おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Cellerant Therapeutics
company
About
Cellerant Therapeutics is a clinical-stage company developing innovative cell- and antibody-based immunotherapies.
- 101 - 250
Details
- Last Funding Type
- Series Unknown
- Last Funding Money Raised
- $2.09M
- Industries
- Biotechnology,Clinical Trials,Therapeutics
- Founded date
- Jan 1, 2003
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Cellerant Therapeutics is a clinical-stage company developing innovative cell- and antibody-based immunotherapies for hematologic malignancies and other blood-related disorders. Cellerant’s Romyelocel-L is a universal cell therapy that does not require HLA matching intended to prevent bacterial and fungal infections during neutropenia. It was founded in 2003 and headquartered in San Carlos, California.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
3
$28.09M
Cellerant Therapeutics has raised a total of
$28.09M
in funding over 2 rounds. Their latest funding was raised on
Sep 28, 2012 from a Series Unknown round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Sep 28, 2012 | Series Unknown | $2.09M | 2 | — | — | Detail |
| May 11, 2005 | Series B | $16M | 2 |
|
— | Detail |
| May 29, 2003 | Series A | $10M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
1
3
Cellerant Therapeutics is funded by 3 investors.
Novel Bioventures
and Camelot Collectables
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
Yes | Series B |
|
|
— | Series Unknown |
Allen & Company
|
— | Series Unknown |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
